HBIO
Harvard Bioscience, Inc.
HBIO trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over HBIO overall, supported by stronger fundamentals and lower modeled downside.
HBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
HBIO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HBIO PE Valuation
HBIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect HBIO's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HBIO on the outlook, with more favorable profitability expectations.
HBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.59 | +$9.51 |
| Q2 2026 | -$2.31 | +$10.59 |
| Q1 2026 | -$2.17 | +$10.93 |
| Q4 2025 | -$12.80 | -$10.00 |
| Q3 2025 | -$12.10 | -$8.80 |
| Q2 2025 | -$12.90 | -$10.40 |
| Q1 2025 | -$13.10 | -$11.10 |
| Q4 2024 | -$2.80 | -$2.00 |
HBIO is still losing money, but far less than before: $2.59 per share over the past year, against $13.10 at its worst in early 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HBIO on earnings quality, reporting a profit while its opponent remains loss making.
HBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.2M | +7.8% |
| Q2 2026 | $22.7M | +11% |
| Q1 2026 | $20.8M | -4.7% |
| Q4 2025 | $23.7M | -3.3% |
| Q3 2025 | $20.6M | -6.3% |
| Q2 2025 | $20.5M | -11% |
| Q1 2025 | $21.8M | -11% |
| Q4 2024 | $24.6M | -13% |
HBIO's revenue is recovering but still below its 2021 peak: $22M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.2% | -6.1 points |
| Q2 2026 | -4.3% | -0.3 points |
| Q1 2026 | -5.7% | +223 points |
| Q4 2025 | 7.2% | +7.2 points |
| Q3 2025 | 1% | +9.5 points |
| Q2 2025 | -4% | +5 points |
| Q1 2025 | -228% | -219 points |
| Q4 2024 | 0% | -1 points |
HBIO's operating margin was −5.2% last quarter, down 6.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HBIO on profitability, with a higher operating margin.
HBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -234% |
| Q2 2026 | -$363K | -114% |
| Q1 2026 | -$1.1M | -144% |
| Q4 2025 | -$545K | -138% |
| Q3 2025 | $877K | +$2.6M |
| Q2 2025 | $2.7M | +$4.3M |
| Q1 2025 | $2.5M | +226% |
| Q4 2024 | $1.4M | -59% |
HBIO's free cash flow has turned negative after years in the green: −$3M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
HBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +35K shares |
| 1 year | +2.4% | +105K shares |
| 3 years | +6.8% | +292K shares |
| 5 years | +15% | +582K shares |
| Available history | +21% | +780K shares |
HBIO has 5M diluted shares, up 2.4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.3x | High |
| Q2 2026 | 6.2x | High |
| Q1 2026 | 5.5x | High |
| Q4 2024 | 43.1x | High |
| Q3 2024 | 30.5x | High |
| Q2 2024 | 15.6x | High |
| Q1 2024 | 6.5x | High |
| Q4 2023 | 3.7x | Elevated |
HBIO's net debt is about 10 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over HBIO on leverage, with a lower net debt burden relative to earnings.
HBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 83.0 | Overbought |
HBIO's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HBIO PE vs Healthcare Sector
HBIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 9.4% above |
| 20 week MA | $7.52 | 22% above |
| 50 week MA | $6.58 | 40% above |
| 100 week MA | $7.00 | 32% above |
| 200 week MA | $23.1 | 60% below |
HBIO has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 60% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HBIO on trend strength, trading above more of its moving averages.
HBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.4 | $40.8 | +39% |
| 2021 | $40.8 | $71.0 | +74% |
| 2022 | $71.0 | $27.3 | -62% |
| 2023 | $27.3 | $53.5 | +96% |
| 2024 | $53.5 | $19.8 | -63% |
| 2025 | $19.8 | $7.02 | -65% |
| 2026 YTD | $7.02 | $9.21 | +31% |
HBIO is up 31% so far in 2026, after finishing lower in three of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HBIO on returns for 2026, with the stronger performance.